

FORM 51-102F3

Material Change Report

Item 1. Name and Address of Company

Blackhawk Growth Corp. (the “Company”)
Suite 2200, 885 West Georgia Street
Vancouver, B.C., V6C 3E8

Item 2. Date of Material Change

News Release dated September 9, 2021.

Item 3. News Release

The Company disseminated a news release concerning the material change described herein on September 9, 2021 and subsequently filed a copy on SEDAR at www.sedar.com.

Item 4. Summary of Material Change

Blackhawk Growth’s Sac Pharma announces record August revenue of CDN\$460,000 and includes operational update.

Item 5. Full Description of Material Change

Vancouver, British Columbia – September 9, 2021 – Blackhawk Growth Corp. (CSE:BLR; Frankfurt:OJJ) (the “**Corporation**” or “**Blackhawk**”), is excited to announce the record unaudited revenue in the month of August for Sac Pharma Partners USA (“**SAC Pharma**”), its wholly owned subsidiary, of CDN\$460,000. Sac Pharma continues to show strong revenue growth. Revenue for the 8 months ended August 31, 2021 is a company record of CDN\$1,842,000. Sac Pharma has also continued to show strong gross margins of greater than 80% and positive cash flow for the year to date. These results are due to increasing facility yields, and the strong demand for Sac Pharma’s premium products.

Sac Pharma is also very excited to announce that the next of its proprietary strains, “*Morada*” has completed the R&D testing approvals and has shown very high producing yield. The robust profile, color and potency has enabled Sac Pharma to be able to have pre-sold the entire production run of the new *Morado* premium product.

“Blackhawk is thrilled with the operating results and the continued development of very desirable proprietary strains”, states Frederick Pels, CEO of Blackhawk. “We are very happy to have such a strong brand in our portfolio of companies.”

Sac Pharma is operating at near capacity and expansion planning has begun.

Sac Pharma's signature products include the coveted Black Truffle, White Truffle strains, along with Bacio and Gelato.

The Company cautions that figures for revenue and margin generated by Sac Pharma have not been audited and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited.

For more information on Blackhawk, please visit our website at:

<https://www.blackhawkgrowth.com/>

About Blackhawk Growth

Blackhawk is an investment holding looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel <https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A>

Please join the conversation on our Blackhawk group supporter's telegram group at <https://t.me/Blackhawkgrowthcorp> and visit us online at <https://www.blackhawkgrowth.com>.

For further information please contact:

Frederick Pels, Chief Executive Officer
(403)-991-7737
fred@blackhawkgrowth.com

Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable

Item 7. Omitted Information

Not applicable

Item 8. Executive Officer

The following senior officer of the Company is knowledgeable about the material change disclosed in this report.

Frederick Pels
Chief Executive Officer
Telephone: 403-991-7737

Item 9. Date of Report

September 9, 2021